Allergan’s 1Q18 Earnings: Analysts’ Estimates

Pharmaceutical giant Allergan (AGN) is set to release its 1Q18 earnings on April 30. Wall Street analysts estimate that the company could report earnings per share (or EPS) of $3.36 on revenues of $3.6 billion for 1Q18.

The chart above compares the company’s EPS and revenues since 1Q17 as well as its estimates for 1Q18. In 4Q17, Allergan reported revenues of $4.3 billion for 11.9% growth compared to 4Q16.

Allergan (AGN) is expected to report 0.6% growth in revenues to $3.59 billion during 1Q18, compared to $3.57 billion during 1Q17. Its 1Q18 revenues are expected to be driven by strong performance of US specialized therapeutics and the favorable impact of foreign exchange.

Analysts expect Allergan’s gross profit margin to decrease to 85.8% during 1Q18, compared to its 1Q17 gross profit margin of 87.3%. Its EBITDA[1. earnings before interest, tax, depreciation, and amortization] margin is expected to increase 0.7% to 47.1% during 1Q18, compared to 46.4% during 1Q17. Its EBITDA margin is expected to increase due to lower selling, general, and administrative (or SG&A) expenses and lower research and development (or R&D) expenses during 1Q18. 

The company’s net adjusted income is expected to decrease to ~$1.18 billion during 1Q18, compared to $1.20 billion during 1Q17.

The VanEck Vectors Biotech ETF (BBH) holds 5.5% of its total investments in Allergan (AGN), 10.7% in Gilead Sciences (GILD), 5.5% in Biogen (BIIB), and 7.6% in Celgene Corporation (CELG).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!